Clinical Overview of PrabotulinumtoxinA for the Investigational Treatment of Frown Lines to Be Featured During Summer Cosmet...
June 22 2018 - 9:33AM
Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a company
dedicated to aesthetic medicine, today announced the presentation
of a comprehensive overview of the clinical program for its
neuromodulator product candidate, DWP-450 (prabotulinumtoxinA), at
the Summer Cosmetic Bootcamp taking place June 21-24, 2018 in
Aspen, CO.
The oral presentation “Toxin Update --
What We Have Now and What is Coming” will be delivered
today during the Neurotoxin University module by Kenneth Beer,
M.D., co-founder of the Cosmetic Bootcamp and voluntary Assistant
Professor at the University of Miami. Dr.
Beer will present top-line results of the Company’s three Phase III
studies, all of which met their respective primary endpoints. This
presentation expands on data presented at the American Academy of
Dermatology (AAD) annual meeting in February 2018.
“My presentation will focus on the current neurotoxin landscape
with an extensive look at what new neurotoxins are going to be
coming to market in the near future,” said Dr. Beer. “If approved,
DWP-450 will be the first new toxin on the market in more than five
years and presents a unique opportunity for physicians given its
aesthetic-only focus.”
"We are pleased that the data from this program will be
presented at Cosmetic Bootcamp, a meeting committed to training and
supporting core aesthetic physicians," said David Moatazedi,
President and Chief Executive Officer of Evolus.
About PrabotulinumtoxinA
PrabotulinumtoxinA is a 900 kDa purified botulinum toxin type A
complex. The product candidate's Biologics License Application
is currently under review by the U.S. Food and Drug Administration
(“FDA”). The product candidate's Marketing Authorization
Application is currently also under review by the European
Medicines Agency (EMA). The FDA application is for the temporary
improvement in the appearance of moderate to severe glabellar lines
associated with corrugator and/or procerus muscle activity in
adults. The EMA application is for temporary improvement in the
appearance of moderate to severe vertical lines between the
eyebrows seen at maximum frown (glabellar lines), when the severity
has an important psychological impact in adult patients.
About Evolus, Inc.
Evolus is a company dedicated to aesthetic medicine focused on
providing physicians and their patients with expanded choices in
aesthetic treatments and procedures. Evolus’ lead candidate
DWP-450, also known by the chemical name prabotulinumtoxinA, is a
900 kDa purified botulinum toxin type A complex that is being
evaluated for the treatment of moderate to severe glabellar
lines.
Evolus Contacts:
Investor Contact: Brian Johnston, The Ruth Group Tel: +1
646-536-7028 Email: IR@Evolus.com
Media: Kirsten Thomas, The Ruth Group Tel: +1-508-280-6592
Email: kthomas@theruthgroup.com
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Apr 2023 to Apr 2024